New drug CT-95 targets tough cancers in early trial

NCT ID NCT06756035

Recruiting now Disease control Sponsor: Context Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new drug called CT-95 in people with advanced cancers that have a protein called mesothelin on their cells. The main goals are to find a safe dose and see if the drug can shrink tumors. About 70 adults with ovarian, lung, pancreatic, or other mesothelin-positive cancers will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA ADVANCED are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Carcinoma, Ovarian Epithelial cholangiocarcinoma colorectal cancer colorectal neoplasm fallopian tube cancer gastric adenocarcinoma gastroesophageal junction adenocarcinoma lung adenocarcinoma malignant epithelioid mesothelioma malignant peritoneal mesothelioma malignant pleural mesothelioma Mesothelioma, Malignant neoplasm Neoplasm Metastasis ovarian carcinoma ovarian epithelial tumor pancreatic adenocarcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHOLANGIOCARCINOMA ADVANCED CHOLANGIOCARCINOMA NON-RESECTABLE COLORECTAL CANCER EPITHELIAL OVARIAN CANCER LUNG ADENOCARCINOMA METASTATIC MALIGNANT PERITONEAL MESOTHELIOMA, ADVANCED MALIGNANT PLEURAL MESOTHELIOMA, ADVANCED MESOTHELIN-EXPRESSING ADVANCED CANCERS MESOTHELIN-EXPRESSING TUMORS MESOTHELIN-POSITIVE ADVANCED MALIGNANT SOLID TUMORS PANCREATIC ADENOCARCINOMA ADVANCED OR METASTATIC

Contacts and locations

Locations

Context Investigational Site
RECRUITING

Denver, Colorado, 80218, United States
Context Investigational Site
RECRUITING

Chicago, Illinois, 60637, United States
Context Investigational Site
RECRUITING

Grand Rapids, Michigan, 49546, United States
Context Investigational Site
RECRUITING

Hackensack, New Jersey, 07601, United States
Context Investigational Site
RECRUITING

Philadelphia, Pennsylvania, 19107, United States
Context Investigational Site
RECRUITING

Nashville, Tennessee, 37203, United States
Context Investigational Site
RECRUITING

San Antonio, Texas, 78229, United States
Context Investigational Site
RECRUITING

San Antonio, Texas, 78229, United States
University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.